Newsbytes
  • India
  • Business
  • World
  • Politics
  • Sports
  • Science
  • Entertainment
  • Auto
  • Lifestyle
  • Inspirational
  • Career
  • Bengaluru
  • Delhi
  • Mumbai
  • Videos
  • Phone Reviews
  • Find Cricket Statistics
Hindi
More
Newsbytes
Hindi
Newsbytes
User Placeholder

Hi,

Logout


India
Business
World
Politics
Sports
Science
Entertainment
Auto
Lifestyle
Inspirational
Career
Bengaluru
Delhi
Mumbai
Videos
Phone Reviews
Find Cricket Statistics

More Links
  • Videos

Download Android App

Follow us on
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
 
Home / News / World News / #GoodNews: Oxford's COVID-19 vaccine may be available by September-end
  • World

    #GoodNews: Oxford's COVID-19 vaccine may be available by September-end

    Shubham Sharma
    Written by
    Shubham Sharma
    Twitter
    Last updated on Jul 17, 2020, 12:40 pm
    #GoodNews: Oxford's COVID-19 vaccine may be available by September-end
  • The COVID-19 vaccine developed by researchers at Oxford University in partnership with AstraZeneca generates an immune response against the infection in humans, The Telegraph reports.

    The official results of the early clinical trial of the shot are still awaited, but people familiar with the study have confirmed that the candidate works and offers 'double defense'.

    Here's more about it.

  • In this article
    Dual protection from the experimental vaccine These two will keep people safe, the official emphasized Results are 'extremely promising' but caution necessary Initial results will be published on Monday, July 20 When will it be available? AstraZeneca is already scaling up manufacturing India will also get this vaccine
  • Details

    Dual protection from the experimental vaccine

    Dual protection from the experimental vaccine
  • Speaking on the results, a senior official involved in Phase-1 of human trials said that the vaccine was able to offer dual protection by generating both antibodies and killer T-cells in the volunteers.

    The development, they said, is significant as separate studies have shown that the immunity from antibodies could disappear after a few months, but T-cells may last for years.

  • Quote

    These two will keep people safe, the official emphasized

  • "I can tell you that we now know the Oxford vaccine covers both bases - it produces both a T-cell and an antibody response. It's the combination of these two that will hopefully keep people safe. So far, so good. It's an important moment."

  • Hope

    Results are 'extremely promising' but caution necessary

  • The source in question noted that these "extremely promising" results from the early trials have made researchers hopeful of a major breakthrough in the fight against the ongoing global pandemic.

    However, the person also clarified that it is yet to be verified if that dual immunity actually remains in the volunteers for years or not.

  • Details

    Initial results will be published on Monday, July 20

  • Notably, the full data related to the Phase-1 study, which had 1,000+ volunteers, will be published on Monday, July 20, in the medical journal The Lancet.

    Meanwhile, the late-stage trials still continue to move forward as planned.

    This particular study is aimed at collecting data related to the efficacy and safety of the vaccine from over 10,000 people in the UK and other nations.

  • Availability

    When will it be available?

    When will it be available?
  • If all goes according to the plan, the vaccine should become available by the end of September or in October.

    "Nobody can put final dates...things might go wrong but the reality is the vaccine could be fairly widely available around September and that is the sort of target they are working on," said David Carpenter, chairman of the committee which approved the Oxford trial.

  • Manufacturing

    AstraZeneca is already scaling up manufacturing

    AstraZeneca is already scaling up manufacturing
  • Even though the results are not yet here, AstraZeneca has struck several partnerships to get sufficient doses of the vaccine produced by the time of results and approval.

    This way, if all goes according to the plan and shot is confirmed to be working and preventing sickness, it will be able to start the distribution immediately in the UK and other countries.

  • India

    India will also get this vaccine

    India will also get this vaccine
  • AstraZeneca has signed deals to supply 400 million doses of the vaccine to the UK and the US, 300 million doses to CEPI, Gavi Vaccine Alliance, 400 million doses to Europe's Inclusive Vaccines Alliance, spearheaded by Germany, France, Italy, and the Netherlands.

    Separately, it has contracted with the Serum Institute of India to supply a billion doses for low-to-middle income countries, including India.

  • Oxford
  • Europe
  • Oxford University
  • United States of America
  • Lancet
  •  
Latest News
  • Mumbai: Two Russians held for performing stunts at sea link
    Mumbai: Two Russians held for performing stunts at sea link
    Mumbai
  • You'll be missed: Harry, Meghan pay tribute to Prince Philip
    You'll be missed: Harry, Meghan pay tribute to Prince Philip
    Entertainment
  • IPL: How does Shikhar Dhawan perform against Chennai Super Kings?
    IPL: How does Shikhar Dhawan perform against Chennai Super Kings?
    Sports
  • Protesting farmers block Kundli-Manesar-Palwal expressway in Haryana
    Protesting farmers block Kundli-Manesar-Palwal expressway in Haryana
    India
  • IPL 2021, SRH vs KKR: Here is the statistical preview
    IPL 2021, SRH vs KKR: Here is the statistical preview
    Sports
Related Timelines
  • Vaccine tracker: Covishield trials running smoothly; COVAXIN expected by February
    Vaccine tracker: Covishield trials running smoothly; COVAXIN expected by February
    Science
  • Vaccine tracker: Covishield expected by December; Moderna readies for launch
    Vaccine tracker: Covishield expected by December; Moderna readies for launch
    Science
  • Oxford COVID-19 vaccine generates immune response among young and old
    Oxford COVID-19 vaccine generates immune response among young and old
    Science
  • Johnson & Johnson's single-dose COVID-19 vaccine induces strong immunity
    Johnson & Johnson's single-dose COVID-19 vaccine induces strong immunity
    Science
Trending Topics
Coronavirus
Next News Article
Share
Cancel

Want to share it with your friends too?

Facebook Whatsapp Twitter Linkedin
Copied

Love World news?

Subscribe to stay updated.

World Thumbnail
India News Business News World News Politics News Sports News Science News Entertainment News Auto News Lifestyle News Inspirational News
Career News Bengaluru News Delhi News Mumbai News Bharti Airtel Mukesh Ambani Indian Premier League Chris Lynn Samsung Virat Kohli
Rohit Sharma Cricket News Mahendra Singh Dhoni YouTube Hollywood News WhatsApp Bollywood News Real Madrid ISRO Yoga
Honda Batman Football News BMW Vaccine Reliance Jio OPPO Food News, Healthy Recipes Apple Tesla
Royal Challengers Bangalore Toyota Fashion Tips Amit Shah Mercedes Sidharth Malhotra Isha Ambani India Vs England Cricket OnePlus Mobiles Android TV
Smart TV Marvel Comics Avengers Neha Kakkar
About Us Privacy Policy Terms & Conditions Contact Us News Reviews News Archive Topics Archive Find Cricket Statistics
Follow us on
Facebook Twitter Linkedin Youtube
All rights reserved © NewsBytes 2021